184 related articles for article (PubMed ID: 20967860)
1. The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
Curtis JR; Xie F; Chen L; Spettell C; McMahan RM; Fernandes J; Delzell E
Arthritis Rheum; 2011 Feb; 63(2):346-51. PubMed ID: 20967860
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.
Curtis JR; Lanas A; John A; Johnson DA; Schulman KL
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1819-28. PubMed ID: 22730417
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
Barbulescu A; Delcoigne B; Askling J; Frisell T
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
[TBL] [Abstract][Full Text] [Related]
5. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.
Gout T; Ostör AJ; Nisar MK
Clin Rheumatol; 2011 Nov; 30(11):1471-4. PubMed ID: 21833686
[TBL] [Abstract][Full Text] [Related]
6. [Incidence rates and risk factors for gastrointestinal perforation in patients with rheumatoid arthritis].
Walz B
Z Rheumatol; 2014 Feb; 73(1):85-6. PubMed ID: 24306840
[No Abstract] [Full Text] [Related]
7. The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.
Závada J; Lunt M; Davies R; Low AS; Mercer LK; Galloway JB; Watson KD; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2014 Jan; 73(1):252-5. PubMed ID: 23644671
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.
Jagpal A; Curtis JR
Drug Saf; 2018 Jun; 41(6):545-553. PubMed ID: 29392593
[TBL] [Abstract][Full Text] [Related]
9. Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.
Curtis JR; Chen SY; Werther W; John A; Johnson DA
Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1150-8. PubMed ID: 22020901
[TBL] [Abstract][Full Text] [Related]
10. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
11. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept.
Rempenault C; Lukas C; Combe B; Herrero A; Pane I; Schaeverbeke T; Wendling D; Pham T; Gottenberg JE; Mariette X; Morel J;
Rheumatology (Oxford); 2022 Mar; 61(3):953-962. PubMed ID: 33993216
[TBL] [Abstract][Full Text] [Related]
12. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
14. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
Wolfe F; Hawley DJ
J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis.
Wilson JC; Sarsour K; Gale S; Pethö-Schramm A; Jick SS; Meier CR
Arthritis Care Res (Hoboken); 2019 Apr; 71(4):498-511. PubMed ID: 29856128
[TBL] [Abstract][Full Text] [Related]
16. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
17. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study.
Myasoedova E; Matteson EL; Talley NJ; Crowson CS
J Rheumatol; 2012 Jul; 39(7):1355-62. PubMed ID: 22467929
[TBL] [Abstract][Full Text] [Related]
19. Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis.
Asai S; Nagai K; Takahashi N; Watanabe T; Matsumoto T; Asai N; Sobue Y; Ishiguro N; Kojima T
Int J Rheum Dis; 2019 Feb; 22(2):207-213. PubMed ID: 30168274
[TBL] [Abstract][Full Text] [Related]
20. Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis.
George MD; Sauer BC; Teng CC; Cannon GW; England BR; Kerr GS; Mikuls TR; Baker JF
J Rheumatol; 2019 Apr; 46(4):343-350. PubMed ID: 30275262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
